|Application ||WB, IHC-P, FC, E|
|Calculated MW||18205 Da|
|Antigen Region||13-40 aa|
|Other Names||Interleukin-31, IL-31, IL31|
|Target/Specificity||This IL31 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 13-40 amino acids from the N-terminal region of human IL31.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||IL31 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Activates STAT3 and possibly STAT1 and STAT5 through the IL31 heterodimeric receptor composed of IL31RA and OSMR (PubMed:15184896). May function in skin immunity (PubMed:15184896). Enhances myeloid progenitor cell survival in vitro (By similarity). Induces RETNLA and serum amyloid A protein expression in macrophages (By similarity).|
|Tissue Location||Detected at low levels in testis, bone marrow, skeletal muscle, kidney, colon, thymus, small intestine and trachea.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
IL31, which is made principally by activated Th2-type T cells, interacts with a heterodimeric receptor consisting of IL31RA (MIM 609510) and OSMR (MIM 601743) that is constitutively expressed on epithelial cells and keratinocytes. IL31 may be involved in the promotion of allergic skin disorders and in regulating other allergic diseases, such as asthma.
Le Saux, S., et al. J. Biol. Chem. 285(5):3470-3477(2010) Zucchelli, M., et al. Inflamm. Bowel Dis. 15(7):961-962(2009) Gutzmer, R., et al. J. Allergy Clin. Immunol. 123(3):619-625(2009) Zhang, Q., et al. Cytokine Growth Factor Rev. 19 (5-6), 347-356 (2008) : Werfel, T., et al. Chem Immunol Allergy 94, 101-111 (2008) :
If you have any additional inquiries please email technical services at firstname.lastname@example.org.